Fennec Pharmaceuticals Reports Hearing Loss Reduction With Pedmark in Japan Phase 2 Trial

No immediate practice change for most audiologists; awareness is warranted that Pedmark (already FDA-approved in the US) is showing consistent ototoxicity (medication-related hearing damage) reduction signals in a Japanese Phase 2 trial, which may prompt earlier referral...